Artículos de revistas
Chronic Myeloid Leukemia Treatment Guidelines: Brazilian Association Of Hematology, Hemotherapy And Cell Therapy. Brazilian Medical Association Guidelines Project - 2012
Registro en:
Revista Brasileira De Hematologia E Hemoterapia. , v. 34, n. 5, p. 367 - 382, 2012.
15168484
10.5581/1516-8484.20120094
2-s2.0-84869040055
Autor
de Souza C.A.
Pagnano K.B.B.
Bendit I.
Conchon M.
Freitas C.M.B.M.
Coelho A.M.
Funke V.A.M.
Bernardo W.M.
Institución
Resumen
[No abstract available] 34 5 367 382 Baccarani, M., Dreyling, M., Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up (2009) Ann Oncol, 20 (4 SUPPL.), pp. 105-107. , ESMO Guidelines Working Group Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes (2009) Blood, 114 (5), pp. 937-951. , Comment in: Blood. 2010;115(3):748-9 author reply 749-50 Tefferi, A., Vardiman, J.W., Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms (2008) Leukemia, 22 (1), pp. 14-22. , Comment in: Leukemia. 2008;22(11):2118-9 Verma, D., Kantarjian, H.M., Jones, D., Luthra, R., Borthakur, G., Verstovsek, S., Chronic myeloid leukemia (CML) with P190 BCR-ABL: Analysis of characteristics, outcomes, and prognostic significance (2009) Blood, 114 (11), pp. 2232-2235 Lucas, C.M., Harris, R.J., Giannoudis, A., Davies, A., Knight, K., Watmough, S.J., Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript (2009) Haematologica, 94 (10), pp. 1362-1367. , Comment in: Haematologica. 2010;95(5):852-3 de Lemos, J.A., de Oliveira, C.M., Scerni, A.C., Bentes, A.Q., Beltrão, A.C., Bentes, I.R., Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia (2005) Genet Mol Res, 4 (4), pp. 803-811 Sharma, P., Kumar, L., Mohanty, S., Kochupillai, V., Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts (2010) Ann Hematol, 89 (3), pp. 241-247 Kreil, S., Pfirrmann, M., Haferlach, C., Waghorn, K., Chase, A., Hehlmann, R., Reiter, A., Cross, N.C., Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia (2007) Blood, 110 (4), pp. 1283-1290. , German Chronic Myelogenous Leukemia (CML) Study Group Ghaith, F., Abdou, S., El-Bendary, A., Shahin, D., Eid, M., Megeed, W.A., Prognostic relevance of 9q34 deletion and the suppressor of cytokine signalling-1 in CML patients (2010) Int J Lab Hematol, 32 (1 PART 2), pp. 103-112 Cohen, N., Rozenfeld-Granot, G., Hardan, I., Brok-Simoni, F., Amariglio, N., Rechavi, G., Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: Expression profiling, resistance to interferon therapy, and poor prognosis (2001) Cancer Genet Cytogenet, 128, pp. 114-119 Quintas-Cardama, A., Kantarjian, H., Talpaz, M., O'Brien, S., Garcia-Manero, G., Verstovsek, S., Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia (2005) Blood, 105 (6), pp. 2281-2286 Quintás-Cardama, A., Kantarjian, H., Shan, J., Jabbour, E., Abruzzo, L.V., Verstovsek, S., Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib (2011) Cancer, 117 (22), pp. 5085-5093 Huntly, B.J., Reid, A.G., Bench, A.J., Campbell, L.J., Telford, N., Shepherd, P., Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia (2001) Blood, 98 (6), pp. 1732-1738. , Comment in: Blood. 2001;98(9):2879-80 Fourouclas, N., Campbell, P.J., Bench, A.J., Swanton, S., Baxter, E.J., Huntly, B.J., Size matters: The prognostic implications of large and small deletions of the derivative 9 chromosome in chronic myeloid leukemia (2006) Haematologica, 91 (7), pp. 952-955 Lee, Y.K., Kim, Y.R., Min, H.C., Oh, B.R., Kim, T.Y., Kim, Y.S., Deletion of any part of the BCR or ABL gene on the derivative chromosome 9 is a poor prognostic marker in chronic myelogenous leukemia (2006) Cancer Genet Cytogenet, 166 (1), pp. 65-73 Vaz de Campos, M.G., Montesano, F.T., Rodrigues, M.M., Chauffaille, M.L., Clinical implications of der(9q) deletions detected through dual-fusion fluorescence in situ hybridization in patients with chronic myeloid leukemia (2007) Cancer Genet Cytogenet, 178 (1), pp. 49-56 Marzocchi, G., Castagnetti, F., Luatti, S., Baldazzi, C., Stacchini, M., Gugliotta, G., Amabile, M., Testoni, N., Variant Philadelphia translocations: Molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis (2011) Blood, 117 (25), pp. 6793-6800. , Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Working Party on Chronic Myeloid Leukemia Castagnetti, F., Testoni, N., Luatti, S., Marzocchi, G., Mancini, M., Kerim, S., Giugliano, E., Rosti, G., Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis (2010) J Clin Oncol, 28 (16), pp. 2748-2754 Landstrom, A.P., Knudson, R.A., Dewald, G.W., Ketterling, R.P., Tefferi, A., Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: Clinical correlates and effect on imatinib mesylate treatment outcome (2007) Leuk Lymphoma, 48 (11), pp. 2137-2140 Gorusu, M., Benn, P., Li, Z., Fang, M., On the genesis and prognosis of variant translocations in chronic myeloid leukemia (2007) Cancer Genet Cytogenet, 173 (2), pp. 97-106 Meggyesi, N., Kozma, A., Halm, G., Nahajevszky, S., Bátai, A., Fekete, S., Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients (2012) Acta Haematol, 127 (1), pp. 34-42 Kim, T.D., Türkmen, S., Schwarz, M., Koca, G., Nogai, H., Bommer, C., Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia (2010) Hematologica, 95 (4), pp. 582-588 Haus, O., Noworolska, A., Laskowski, M., Kuliszkiewicz-Janus, M., Kozlowska, J., Harlozinska-Szmyrka, A., Prognostic significance of secondary cytogenetic changes and nonspecific cross-reacting antigen (NCA) in patients with Ph-positive chronic myeloid leukemia (1990) Exp Mol Pathol, 52 (2), pp. 235-242 Hsiao, H.H., Liu, Y.C., Tsai, H.J., Hsu, J.F., Yang, W.C., Chang, C.S., Additional chromosome abnormalities in chronic myeloid leukemia (2011) Kaohsiung J Med Sci, 2 (27), pp. 49-54 Vranová, V., Katina, S., Kirschnerová, G., Mistrík, M., Lakota, J., Horáková, J., A significance of additional chromosomal aberrations and other variables on post transplantation outcome of patients with CML (2005) Neoplasma, 52 (5), pp. 381-387 Fabarius, A., Leitner, A., Hochhaus, A., Müller, M.C., Hanfstein, B., Haferlach, C., Göhring, G., Hehlmann, R., Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: Long-term observation of 1151 patients from the randomized CML Study IV (2011) Blood, 118 (26), pp. 6760-6768. , Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) and the German CML Study Group Ahmed, R., Naqi, N., Hussain, I., Khattak, B.K., Nadeem, M., Iqbal, J., Presentating phases of chronic myeloid leukaemia (2009) J Coll Physicians Surg Pak, 19 (8), pp. 469-472 Cortes, J., Kantarjian, H., Advanced-phase chronic myeloid leukemia (2003) Semin Hematol, 40 (1), pp. 79-86 Cortes, J.E., Talpaz, M., O'Brien, S., Faderl, S., Garcia-Manero, G., Ferrajoli, A., Staging of chronic myeloid leukemia in the imatinib era: An evaluation of the World Health Organization proposal (2006) Cancer, 106 (6), pp. 1306-1315 Cortes, J., Natural history and staging of chronic myelogenous leukemia (2004) Hematol Oncol Clin North Am, 18 (3), pp. 569-84+8 Aguayo, A., Couban, S., State-of-the-art in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors: Evolutionary trends in diagnosis, monitoring and treatment (2009) Leuk Lymphoma, 50 (2 SUPPL.), pp. 1-8 O'Brien, S.G., Guilhot, F., Larson, R.A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J.J., Druker, B.J., Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia (2003) N Engl J Med, 348 (11), pp. 994-1004. , IRIS Investigators Bonifazi, F., de Vivo, A., Rosti, G., Tiribelli, M., Russo, D., Trabacchi, E., Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon (2000) Br J Haematol, 111 (2), pp. 587-595. , Italian Cooperative Study Group on Chronic Myeloid Leukaemia Corm, S., Roche, L., Micol, J.B., Coiteux, V., Bossard, N., Nicolini, F.E., Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: A population study (2011) Blood, 118 (16), pp. 4331-4337 Druker, B.J., Guilhot, F., O'Brien, S.G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M.W., Larson, R.A., Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia (2006) N Engl J Med, 355 (23), pp. 2408-2417. , IRIS Investigators Deenik, W., Janssen, J.J., van der Holt, B., Verhoef, G.E., Smit, W.M., Kersten, M.J., Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia (2010) Haematologica, 95 (6), pp. 914-921 Forrest, D.L., Trainor, S., Brinkman, R.R., Barnett, M.J., Hogge, D.E., Nevill, T.J., Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels (2009) Leuk Res, 33 (2), pp. 271-275. , Comment in: Leuk Res. 2009;33(8):1147-8 author reply 1149-50 Hasford, J., Pfirrmann, M., Hehlmann, R., Baccarani, M., Guilhot, F., Mahon, F.X., Kluin-Nelemans, H.C., Steegmann, J.L., Prognosis and prognostic factors for patients with chronic myeloid leukemia: Nontransplant therapy (2003) Semin Hematol, 40 (1), pp. 4-12. , Collaborative CML Prognostic Factors Project Group Rajappa, S., Varadpande, L., Paul, T., Jacob, R., Digumarti, R., Imatinib mesylate in early chronic phase chronic myeloid leukemia: Experience From a Developing Country (2008) Leuk Lymphoma, 49 (3), pp. 554-558 Lee, J.P., Birnstein, E., Masiello, D., Yang, D., Yang, A.S., Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: A single-institution retrospective study (2009) J Hematol Oncol, 2, p. 30 Kantarjian, H., Shah, N.P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia (2010) N Engl J Med, 362 (24), pp. 2260-2270. , Comment in: N Engl J Med. 2010;362(24):2314-5. N Engl J Med. 2010;363(17):1672- 3 author reply 1673-5. Expert Opin Pharmacother. 2011;12(1):157-63. N Engl J Med. 2010;363(17):1673;author reply 1673-5 Kantarjian, H.M., Shah, N.P., Cortes, J.E., Baccarani, M., Agarwal, M.B., Undurraga, M.S., Dasatinib or imatinib in newly diagnosed chronicphase chronic myeloid leukemia: 2 year follow-up from a randomized phase 3 trial (DASISION) (2012) Blood, 119 (5), pp. 1123-1129 Saglio, G., Kim, D.W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Kantarjian, H.M., Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia (2010) N Engl J Med, 362 (24), pp. 2251-2259. , ENESTnd Investigators, Comment in: N Engl J Med. 2010;362(24):2314-5 N Engl J Med. 2010;363(17):1672 author reply 1673-5 Expert Opin Pharmacother. 2011;12(1):157-63 N Engl J Med. 2010;363(17):1673 author reply 1673-5 Kantarjian, H.M., Hochhaus, A., Saglio, G., de Souza, C., Flinn, I.W., Stenke, L., Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial (2011) Lancet Oncol, 12 (9), pp. 841-851. , Comment in: Lancet Oncol. 2011;12(9):826-7 Breccia, M., Stefanizzi, C., Cannella, L., Latagliata, R., Frustaci, A.M., Carmosino, I., Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia (2008) Leuk Lymphoma, 49 (12), pp. 2328-2332 Scerni, A.C., Alvares, L.A., Beltrão, A.C., Bentes, I.R., Azevedo, T.C., Bentes, A.Q., Influence of late treatment on how chronic myeloid leukemia responds to imatinib (2009) Clinics (Sao Paulo), 64 (8), pp. 731-734 Cortes, J.E., Talpaz, M., Giles, F., O'Brien, S., Rios, M.B., Shan, J., Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy (2003) Blood, 101 (10), pp. 3794-3800 Kantarjian, H.M., Cortes, J.E., O'Brien, S., Luthra, R., Giles, F., Verstovsek, S., Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha (2004) Blood, 104 (7), pp. 1979-1988 Palandri, F., Iacobucci, I., Martinelli, G., Amabile, M., Poerio, A., Testoni, N., Soverini, S., Baccarani, M., Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: The GIMEMA Working Party on CML (2008) J Clin Oncol, 26 (1), pp. 106-111. , GIMEMA Working Party on CML Gambacorti-Passerini, C., Antolini, L., Mahon, F.X., Guilhot, F., Deininger, M., Fava, C., Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib (2011) J Natl Cancer Inst, 103 (7), pp. 553-561. , Comment in: J Natl Cancer Inst. 2011;103(7):527-9 Fava, C., Kantarjian, H.M., Jabbour, E., O'Brien, S., Jain, N., Rios, M.B., Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase (2009) Blood, 113 (21), pp. 5058-5063 Milojkovic, D., Nicholson, E., Apperley, J.F., Holyoake, T.L., Shepherd, P., Drummond, M.W., Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia (2010) Haematologica, 95 (2), pp. 224-231 Marin, D., Kaeda, J., Szydlo, R., Saunders, S., Fleming, A., Howard, J., Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: Patterns of residual leukaemia and prognostic factors for cytogenetic relapse (2005) Leukemia, 19 (4), pp. 507-512 Furukawa, T., Narita, M., Koike, T., Takai, K., Nagai, K., Kobayashi, M., Koyama, S., Clinical value of assessing the response to imatinib monitored by interphase FISH and RQ-PCR for BCR-ABL in peripheral blood for long-term survival of chronic phase CML patients: Results of the Niigata CML-multi-institutional co-operative clinical study (2011) Int J Hematol, 93 (3), pp. 336-343 Cortes, J.E., Kantarjian, H.M., Goldberg, S.L., Powell, B.L., Giles, F.J., Wetzler, M., Akard, L., Radich, J., High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: High rates of rapid cytogenetic and molecular responses (2009) J Clin Oncol, 27 (28), pp. 4754-4759. , Rationale and Insight for Gleevec High-Dose, Therapy (RIGHT) Trial Study Group Ross, D.M., Branford, S., Moore, S., Hughes, T.P., Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL (2006) Leukemia, 20 (4), pp. 664-670 Press, R.D., Galderisi, C., Yang, R., Rempfer, C., Willis, S.G., Mauro, M.J., A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response (2007) Clin Cancer Res, 13 (20), pp. 6136-6143 Lange, T., Bumm, T., Otto, S., Al-Ali, H.K., Kovacs, I., Krug, D., Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy (2004) Haematologica, 89 (1), pp. 49-57. , Comment in: Haematologica. 2004 89(1):6-9 Lima, L., Bernal-Mizrachi, L., Saxe, D., Mann, K.P., Tighiouart, M., Arellano, M., Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond (2011) Cancer, 117 (6), pp. 1245-1252 Kantarjian, H., Pasquini, R., Hamerschlak, N., Rousselot, P., Holowiecki, J., Jootar, S., Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial (2007) Blood, 109 (12), pp. 5143-5150 Kantarjian, H., Pasquini, R., Lévy, V., Jootar, S., Holowiecki, J., Hamerschlak, N., Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: Two-year follow-up of a randomized phase 2 study (START-R) (2009) Cancer, 115 (18), pp. 4136-4147 Shah, N.P., Kantarjian, H.M., Kim, D.W., Réa, D., Dorlhiac-Llacer, P.E., Milone, J.H., Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib- resistant and-intolerant chronic-phase chronic myeloid leukemia (2008) J ClinOncol, 26 (19), pp. 3204-3212. , Comment in: Nat Clin Pract Oncol. 2009;6(2):68-9 Shah, N.P., Kim, D.W., Kantarjian, H., Rousselot, P., Llacer, P.E., Enrico, A., Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimalresponse or intolerance to imatinib (2010) Haematologica, 95 (2), pp. 232-240 Koren-Michowitz, M., le Coutre, P., Duyster, J., Scheid, C., Panayiotidis, P., Prejzner, W., Activity and tolerability of nilotinib: A retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant (2010) Cancer, 116 (19), pp. 4564-4572 Kantarjian, H.M., Giles, F., Gattermann, N., Bhalla, K., Alimena, G., Palandri, F., Nilotinib (formerlyAMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective inpatients with Philadelphia chromosome- positive chronic myelogenous leukemia inchronic phase following imatinib resistance and intolerance (2007) Blood, 110 (10), pp. 3540-3546 Kantarjian, H.M., Giles, F.J., Bhalla, K.N., Pinilla-Ibarz, J., Larson, R.A., Gattermann, N., Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase afterimatinib resistance or intolerance: 24-month follow-up results (2011) Blood, 117 (4), pp. 1141-1145 Giles, F.J., Abruzzese, E., Rosti, G., Kim, D.W., Bhatia, R., Bosly, A., Nilotinib is active in chronic and accelerated phase chronic myeloid leukemiafollowing failure of imatiniband dasatinib therapy (2010) Leukemia, 24 (7), pp. 1299-1301 Khoury, H.J., Cortes, J.E., Kantarjian, H.M., Gambacorti-Passerini, C., Baccarani, M., Kim, D.W., Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure (2012) Blood, 119 (15), pp. 3403-3412 Noens, L., van Lierde, M.A., de Bock, R., Verhoef, G., Zachée, P., Berneman, Z., Martiat, P., Abraham, I., Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study (2009) Blood, 113 (22), pp. 5401-5411 Marin, D., Bazeos, A., Mahon, F.X., Eliasson, L., Milojkovic, D., Bua, M., Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib (2010) J Clin Oncol, 28 (14), pp. 2381-2388 Ibrahim, A.R., Eliasson, L., Apperley, J.F., Milojkovic, D., Bua, M., Szydlo, R., Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy (2011) Blood, 117 (14), pp. 3733-3736 Ganesan, P., Sagar, T.G., Dubashi, B., Rajendranath, R., Kannan, K., Cyriac, S., Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia (2011) Am J Hematol, 86 (6), pp. 471-474 Jabbour, E., Kantarjian, H., O'Brien, S., Shan, J., Garcia-Manero, G., Wierda, W., Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure (2011) Blood, 117 (6), pp. 1822-1827. , Comment in: Blood. 2011 117(6):1773-4 Branford, S., Rudzki, Z., Walsh, S., Parkinson, I., Grigg, A., Szer, J., Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis (2003) Blood, 102 (1), pp. 276-283 Soverini, S., Martinelli, G., Rosti, G., Bassi, S., Amabile, M., Poerio, A., ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA Working Party on Chronic Myeloid Leukemia (2005) J Clin Oncol, 23 (18), pp. 4100-4109 Jabbour, E., Kantarjian, H., Jones, D., Talpaz, M., Bekele, N., O'Brien, S., Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate (2006) Leukemia, 20 (10), pp. 1767-1773 Khorashad, J.S., de Lavallade, H., Apperley, J.F., Milojkovic, D., Reid, A.G., Bua, M., Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression (2008) J Clin Oncol, 26 (29), pp. 4806-4813 Jabbour, E., Jones, D., Kantarjian, H.M., O'Brien, S., Tam, C., Koller, C., Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations (2009) Blood, 114 (10), pp. 2037-2043 Ono, T., Miyawaki, S., Kimura, F., Kanamori, H., Ohtake, S., Kitamura, K., Fujita, H., Ohnishi, K., BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assay (2011) Leuk Res, 35 (5), pp. 598-603. , Japan Adult Leukemia Study Group Kim, T.D., Türkmen, S., Schwarz, M., Koca, G., Nogai, H., Bommer, C., Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia (2010) Haematologica, 95 (4), pp. 582-588 Müller, M.C., Cortes, J.E., Kim, D.W., Druker, B.J., Erben, P., Pasquini, R., Dasatinib treatment of chronic-phase chronic myeloid leukemia: Analysis of responses according to preexisting BCR-ABL mutations (2009) Blood, 114 (24), pp. 4944-4953. , Comment in: Blood. 2009;114(24):4914-5 O'Hare, T., Eide, C.A., Deininger, M.W., Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia (2007) Blood, 110 (7), pp. 2242-2249 Redaelli, S., Piazza, R., Rostagno, R., Magistroni, V., Perini, P., Marega, M., Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants (2009) J Clin Oncol, 27 (3), pp. 469-471. , Comment in: J Clin Oncol. 2010;28(11):e169-71 author reply e172 Hughes, T., Saglio, G., Branford, S., Soverini, S., Kim, D.W., Müller, M.C., Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase (2009) J Clin Oncol, 27 (25), pp. 4204-4210 Branford, S., Melo, J.V., Hughes, T.P., Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: Does the BCR-ABL mutation status really matter? (2009) Blood, 114 (27), pp. 5426-5435 Parker, W.T., Lawrence, R.M., Ho, M., Irwin, D.L., Scott, H.S., Hughes, T.P., Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy (2011) J Clin Oncol, 29 (32), pp. 4250-4259 Wang, L., Pearson, K., Pillitteri, L., Ferguson, J.E., Clark, R.E., Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia (2002) Br J Haematol, 118 (3), pp. 771-777 Hughes, T.P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M.L., Gathmann, I., Radich, J.P., Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia (2003) N Engl J Med, 349 (15), pp. 1423-1432. , International Randomised Study of Interferon versus STI571 (IRIS) Study Group, Comment in: N Engl J Med. 2003;349(15):1399-401 Branford, S., Fletcher, L., Cross, N.C., Müller, M.C., Hochhaus, A., Kim, D.W., Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials (2008) Blood, 112 (8), pp. 3330-3338 Picard, S., Titier, K., Etienne, G., Teilhet, E., Ducint, D., Bernard, M.A., Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia (2007) Blood, 109 (8), pp. 3496-3499. , Comment in: Blood. 2007;110(5):1699-701 author reply 1701 Reinhold, U., Hennig, E., Leiblein, S., Niederwieser, D., Deininger, M.W., FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib (2003) Leukemia, 17 (10), pp. 1925-1929 Mascarenhas, C.C., Cunha, A.F., Miranda, E.C., Zulli, R., Silveira, R.A., Costa, F.F., New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors (2009) Leuk Lymphoma, 50 (7), pp. 1148-1154 Olavarria, E., Ottmann, O.G., Deininger, M., Clark, R.E., Bandini, G., Byrne, J., Lipton, J., Fischer, T., Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia (2003) Leukemia, 17 (9), pp. 1707-1712. , Chronic Leukaemia Working Party of, the European Group of Bone and Marrow Transplantation (EBMT), Comment in: Leukemia. 2003;17(9):1722 Crawley, C., Szydlo, R., Lalancette, M., Bacigalupo, A., Lange, A., Brune, M., Juliusson, G., Apperley, J.F., Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: An analysis of prognostic factors from the ChronicLeukemia Working Party of the EBMT (2005) Blood, 106 (9), pp. 2969-2976. , Chronic Leukemia Working Party of the EBMT Lee, S.J., Kukreja, M., Wang, T., Giralt, S.A., Szer, J., Arora, M., Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloidleukemia (2008) Blood, 112 (8), pp. 3500-3507 Burke, M.J., Trotz, B., Luo, X., Weisdorf, D.J., Baker, K.S., Wagner, J.E., Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemiapatients (2009) Bone Marrow Transplant, 44 (3), pp. 169-174 Luo, Y., Zhao, Y., Tan, Y., Shi, J., Han, X., Zheng, Y., Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia (2011) Leuk Res, 35 (10), pp. 1307-1311 Jiang, Q., Xu, L., Liu, D., Liu, K., Chen, S., Jiang, B., Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase (2011) Blood, 117 (11), pp. 3032-3040 Boehm, A., Walcherberger, B., Sperr, W.R., Wöhrer, S., Dieckmann, K., Rosenmayr, A., Improved outcome in patients with chronic myelogenous leukemia after allogeneichematopoietic stem cell transplantation over the past 25 years: A single-centerexperience (2011) Biol Blood Marrow Transplant, 17 (1), pp. 133-140 Breccia, M., Palandri, F., Iori, A.P., Colaci, E., Latagliata, R., Castagnetti, F., Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib (2010) Leuk Res, 34 (2), pp. 143-147 Millot, F., Baruchel, A., Guilhot, J., Petit, A., Leblanc, T., Bertrand, Y., Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: Results of the French national phase IV trial (2011) J Clin Oncol, 29 (20), pp. 2827-2832 Suttorp, M., Claviez, A., Bader, P., Peters, C., Gadner, H., Ebell, W., Dilloo, D., Padiatr, K., Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: Results from the prospective trial CML-paed I (2009) Klin Padiatr, 221 (6), pp. 351-357